Creative Biolabs Inc., the U.S-based life-science firm offering biotech products and services for early drug discovery and development, has reportedly announced that it is exploring new fields in precision medicine to develop novel treatments for life-threatening diseases like cancer.
From gene to bio-therapeutics, the life science firm has already introduced integrated protein and therapeutic antibody platforms. These platforms cover the complete pipeline that is composed of biologics testing, discovery, preclinical testing, development, IND regulatory service, cGMP manufacturing, and modality.
Biological assays are able to give out complete information about drugs' biological activities by observing their impacts on living animals or tissues. It can also detect biohazards, providing a top-quality evaluation of mixtures, evaluates environmental impact, and assess the safety of new technology and facilities.
Creative Biolabs has all-inclusive biologics testing services (structure characterization, immunoassay, post-translational modification, biomarker development, etc.) that are offered by the veterans in oncology immunotherapy, covering the complete drug development cycle and guaranteed to be in accordance with GMP regulations.
According to sources familiar with the knowledge of matter, complete workflow follows the authoritative rules and regulations (EMA, FDA). Moreover, this enables healthcare organizations to perform all-around testing, including microbiology, microbiology, and molecular biology.
The Shirley-based firm developed numerous development platforms to advance the research in immunotherapy in crucial stages, which are aided by top-notch GMP (Good Manufacturing Practice) manufacturing facilities.
The almighty service portfolio comprises cell banking, cell line development, cell link characterization, purification development, cell culture process development, formulation development, and so on. Among which the cell line development is popular among healthcare companies requiring a stable cell line that is outstanding in developing recombinant protein and monoclonal antibody. Moreover, the company can handle process development, cell line construction, cell analysis, cell banking, and other corresponding projects.
Source credit - https://menafn.com/1101074033/Creative-Biolabs-Immuno-Oncology-Programs-Enable-Efficient-Development-of-Innovative-Therapeutic-Candidates